Neurology Market
A new era of disease-modifying therapies in Alzheimer's, MS, and rare neurological disorders
Market Overview
The neurology market is experiencing a paradigm shift with the first disease-modifying Alzheimer's therapies (lecanemab, donanemab), next-generation MS treatments, and breakthrough gene therapies for rare neurological disorders. After decades of pipeline failures, neurology is re-emerging as one of the most attractive therapeutic areas for pharmaceutical investment, driven by validated biological targets and biomarker-driven patient selection.
Market Size Forecast (2024–2030)
Projected market value in USD billions
Market Segments
Share by therapeutic segment
Regional Market Analysis
Market share and growth by region
Key Drivers
- ▸Anti-amyloid Alzheimer's therapies (lecanemab, donanemab) creating a new $15B+ market
- ▸Next-generation MS therapies with improved safety profiles (BTK inhibitors, anti-CD20s)
- ▸Gene therapies for rare neurological disorders (SMA, DMD, ALS)
- ▸Biomarker-driven patient stratification improving trial success rates
- ▸Growing prevalence of neurodegenerative diseases with aging populations
- ▸Regulatory flexibility and accelerated pathways for neurological orphan diseases
Challenges
- ▸High clinical trial failure rates in neurology historically
- ▸Reimbursement challenges for expensive Alzheimer's therapies with monitoring requirements
- ▸Safety concerns (ARIA) with anti-amyloid antibodies requiring MRI monitoring
- ▸Long trial durations for neurodegenerative disease endpoints
- ▸Diagnostic infrastructure gaps for early Alzheimer's detection
Opportunities
- ▸Alzheimer's disease market projected to reach $15B+ by 2030
- ▸BTK inhibitor pipeline in MS representing $5B+ opportunity
- ▸Rare neurological disorders with 200+ pipeline programs and orphan benefits
- ▸Neuroinflammation emerging as a validated target across multiple indications
- ▸Digital biomarkers and remote monitoring enabling decentralized trials
- ▸Gene therapy platforms applicable across multiple neurological indications
Key Pipeline Drugs
Late-stage and recently approved therapies from Top 20 pharma
| Drug | Company | Phase |
|---|---|---|
Leqembi (lecanemab) Early Alzheimer's disease | Eisai / Biogen | Approved |
Kisunla (donanemab) Early Alzheimer's disease | Eli Lilly | Approved |
Evobrutinib Relapsing-remitting MS | Merck KGaA | Phase 3 |
Remibrutinib Relapsing MS | Novartis | Phase 3 |
Tofersen SOD1-ALS | Biogen / Ionis | Approved (accelerated) |
Elevidys (delandistrogene moxeparvovec) Duchenne muscular dystrophy | Sarepta / Roche | Approved |
Vamorolone Duchenne muscular dystrophy | Santhera | Approved |
Ublituximab Relapsing MS | TG Therapeutics | Approved |
Marketed Drugs — Current Landscape
Blockbuster and key marketed therapies shaping the competitive landscape
| Drug | Company | Annual Sales |
|---|---|---|
Ocrevus (ocrelizumab) MS market leader (RRMS + PPMS) | Roche | $6B+ |
Aubagio (teriflunomide) Mature oral MS therapy | Sanofi | $1B+ |
Botox (onabotulinumtoxinA) Multiple neurological indications | AbbVie | $3B+ (neurology) |
Aimovig (erenumab) Migraine prevention leader | Amgen / Novartis | $1B+ |
Spinraza (nusinersen) SMA standard of care | Biogen / Ionis | $2B+ |
Vyvanse (lisdexamfetamine) ADHD market leader | Takeda | $2B+ |
Tecfidera (dimethyl fumarate) Mature oral MS therapy | Biogen | $2B+ |
Xyrem (sodium oxybate) Narcolepsy standard | Jazz Pharmaceuticals | $1.5B+ |
Competitive Landscape
Tiered analysis of companies shaping the neurology market
Tier 1 — Neurology Leaders
Dominant MS and Alzheimer's franchises with broad neurology portfolios
Tier 2 — Specialty Neurology
Strong positions in migraine, movement disorders, and epilepsy
Tier 3 — Gene Therapy Pioneers
Leading gene therapy platforms for rare neurological diseases
Our Research Methodology
KOL Network
35+ interviews with neurologists, neuropsychologists, radiologists, and patient advocates across US, EU5, and Japan to validate treatment paradigms and diagnostic pathways.
Epidemiological Modeling
Age-stratified prevalence and incidence modeling for Alzheimer's, MS, Parkinson's, epilepsy, and rare neurological disorders using global registry data.
Pipeline Intelligence
Tracking of 800+ neurology pipeline assets with focus on mechanism of action, trial design, biomarker strategy, and regulatory milestones.
Diagnostic Infrastructure Analysis
Assessment of amyloid PET, CSF biomarker, and blood-based biomarker adoption rates to model Alzheimer's therapy market access.
Payer & Access Modeling
Reimbursement scenario analysis for high-cost neurology therapies including gene therapies and anti-amyloid antibodies with monitoring cost modeling.
How We Help Clients Win in Neurology
Our consulting engagements combine deep therapeutic expertise with proprietary intelligence to identify where the opportunity lies — and how to capture it.
Alzheimer's Market Entry
Navigate the complex Alzheimer's market with diagnostic infrastructure, payer access, and KOL engagement strategies
Rare Neurology Portfolio Strategy
Identify and evaluate rare neurological indications with orphan benefits and gene therapy applicability
MS Competitive Positioning
Model impact of BTK inhibitors and next-gen anti-CD20s on your MS franchise
Biomarker Strategy
Develop biomarker-driven patient stratification strategies for neurology trials and commercial positioning
Frequently Asked Questions
What is driving the growth in the neurology pharmaceutical market?
The neurology market is being transformed by the first disease-modifying Alzheimer's therapies (lecanemab, donanemab), next-generation MS treatments (BTK inhibitors), and breakthrough gene therapies for rare neurological disorders. These innovations are creating $20B+ in new market opportunities.
How large is the Alzheimer's disease pharmaceutical market?
The Alzheimer's disease market is projected to reach $15B+ by 2030, driven by anti-amyloid antibody therapies (Leqembi, Kisunla) and emerging tau-targeting therapies. However, market realization depends on diagnostic infrastructure expansion and payer access.
What consulting services does Medifirm offer for neurology?
We provide neurology market intelligence including epidemiological modeling, competitive landscape analysis, KOL engagement, diagnostic infrastructure assessment, payer access strategy, and pipeline gap analysis tailored to Alzheimer's, MS, rare neurology, and other neurological indications.